Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05548452 · ClinicalTrials.gov registry record · Phase 1
Intestinal Microbiota Transplant in Alcohol-Associated Liver Disease
A Phase 1 study of Alcohol Use Disorder and Cirrhosis, sponsored by Virginia Commonwealth University.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 80
- Enrollment target
- 2
- Study locations
NCT05548452: Recruiting Phase 1 study of Alcohol Use Disorder and Cirrhosis, sponsored by Virginia Commonwealth University.
NCT05548452 is a Phase 1 study of Alcohol Use Disorder and Cirrhosis that is actively recruiting participants, run by Virginia Commonwealth University. The registered enrollment target is 80 participants, below the 328-participant average among 184 other Alcohol Use Disorder trials with a reported enrollment target (76% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05548452, a Phase 1 study of Alcohol Use Disorder and Cirrhosis, is actively recruiting participants, sponsored by Virginia Commonwealth University.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 80 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this research study is to test the safety, tolerability, and effectiveness of the capsules that contain bacteria from healthy individuals when used to treat alcohol craving and drinking.
Primary Outcome
Number of drinks per day will be measured through self report
Conditions Studied
Interventions
- DRUG Intestinal Microbiota Transplant (IMT) Capsules
- DRUG Placebo Capsules
Study Locations (2)
Virginia
- Hunter Holmes McGuire VA Medical Center - Richmond
- Virginia Commonwealth University - Richmond
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2022-11-21 |
| Est. Completion | 2026-12-30 |
| Phase | Phase 1 |
What NCT05548452 shows while recruiting
NCT05548452 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 80 participants, a relatively small participant target, below the 328-participant average among 184 other Alcohol Use Disorder trials with a reported enrollment target (76% lower).
The record links to 3 conditions, with Alcohol Use Disorder appearing as the primary indexed condition, and to 2 interventions - of which Intestinal Microbiota Transplant (IMT) Capsules is the first listed.
NCT05548452 reports a single indexed study location in Virginia.
Frequently Asked Questions
What is clinical trial NCT05548452 about?
NCT05548452 is a clinical study titled "Intestinal Microbiota Transplant in Alcohol-Associated Liver Disease". The purpose of this research study is to test the safety, tolerability, and effectiveness of the capsules that contain bacteria from healthy individuals when used to treat alcohol craving and drinking.
What is the current status of trial NCT05548452?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 80 participants. The study started on 2022-11-21. Estimated completion is 2026-12-30.
What conditions does trial NCT05548452 study?
This clinical trial studies the following conditions: Alcohol Use Disorder, Cirrhosis, Liver Disease; Alcohol-Related.
What interventions are being tested in trial NCT05548452?
The interventions under investigation include: Intestinal Microbiota Transplant (IMT) Capsules (DRUG), Placebo Capsules (DRUG).
Who is sponsoring clinical trial NCT05548452?
This trial is sponsored by Virginia Commonwealth University, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05548452 being conducted?
This trial has 2 study locations across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alcohol Use Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05548452's enrollment target sits among peer trials
80 100th of 184 higher than 79 of 184 other Alcohol Use Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Alcohol Use Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Intranasal Insulin for Treatment of Alcohol Use Disorder
RECRUITING · Phase 1
-
Acute Effects of Alcohol on PET Imaging of Phosphodiesterase-4B (PDE4B)
RECRUITING · Phase 1
-
Environment and Alcohol: A Pilot Study
RECRUITING · Phase 1
-
PET Imaging of Phosphodiesterase-4B (PDE4B) in Alcohol Use Disorder
RECRUITING · Phase 1
-
Sex Differences in the Response to Abstinence From Alcohol.
RECRUITING · Phase 1
-
PT150 Drug for Use in Alcohol Use Disorder
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
- NCT01659203 · 80 participants · Phase 1
Proton or Photon RT for Retroperitoneal Sarcomas
- NCT01803451 · 80 participants · Early Phase 1
Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass
- NCT01964859 · 80 participants · Phase 2
Feasibility Study for Fibroblast Autologous Skin Grafts
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI